Matrix metalloproteinases in skin
- 1 October 1997
- journal article
- review article
- Published by Wiley in Experimental Dermatology
- Vol. 6 (5) , 199-213
- https://doi.org/10.1111/j.1600-0625.1997.tb00164.x
Abstract
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases collectively capable of degrading essentially all extracellular matrix components. These enzymes can be produced by several different types of cells in skin such as fibroblasts, keratinocytes, macrophages, endothelial cells, mast cells, and eosinophils and their activity can be specifically inhibited by TIMPs (tissue inhibitors of metalloproteinases), which bind to active MMPs with 1:1 stoichiometry. In general, MMPs are not constitutively expressed in skin but are induced temporarily in response to exogenous signals such as various cytokines, growth factors, cell matrix interactions and altered cell-cell contacts. At present, more evidence is accumulating that MMPs play an important role in proteolytic remodeling of extracellular matrix in various physiologic situations, including developmental tissue morphogenesis, tissue repair, and angiogenesis. On the other hand, MMPs play an important pathogenetic role in excessive breakdown of connective tissue components, e.g. in rheumatoid arthritis, osteoarthritis, chronic ulcers, dermal photoageing, and periodontitis, as well as in tumor cell invasion and metastasis. In this review we discuss the role of MMPs and TIMPs in human skin based on new observations on the regulation of the expression of MMPs, on their substrate specificity, and MMP expression in physiologic and pathologic conditions of skin involving matrix remodeling. Furthermore, therapeutic modalities based on regulating MMP activity will be reviewed.Keywords
This publication has 126 references indexed in Scilit:
- Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancerEuropean Journal Of Cancer, 1996
- Long-term sun exposure alters the collagen of thepapillary dermisJournal of the American Academy of Dermatology, 1996
- Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosisJournal of the American Academy of Dermatology, 1995
- The human collagenase-3 (CLG3) gene is located on chromosome 11q22.3 clustered to other members of the matrix metalloproteinase gene familyGenomics, 1995
- Uncoordinate regulation of collagenase, stromelysin, and tissue inhibitor of metalloproteinases genes by prostaglandin E2: Selective enhancement of collagenase gene expression in human dermal fibroblasts in cultureJournal of Cellular Biochemistry, 1994
- Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a reviewBreast Cancer Research and Treatment, 1993
- Selective endothelial growth inhibition by tetracyclines that inhibit collagenaseBiochemical and Biophysical Research Communications, 1992
- Increased gene expression of matrix metalloproteinase-3 (stromelysin) in skin fibroblasts from patients with severe recessive dystrophic epidermolysis bullosaBiochemical and Biophysical Research Communications, 1991
- Elevated Levels of Human Collagenase Inhibitor in Blister Fluids of Diverse EtiologyJournal of Investigative Dermatology, 1986
- Human Skin Collagenase: Relationship to the Pathogenesis of Epidermolysis Bullosa Dystrophica*Journal of Investigative Dermatology, 1969